Melinta Therap Drug Patent Portfolio

Melinta Therap owns 2 orange book drugs protected by 5 US patents Given below is the list of Melinta Therap's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9649352 High purity oritavancin and method of producing same 16 Jul, 2035
Active
US9682061 Methods of treating bacterial infections using oritavancin 26 Apr, 2030
Active
US8420592 Methods of treatment using single doses of oritavancin 29 Aug, 2029
Active
US5840684 Glycopeptide antibiotic derivatives 24 Nov, 2020 Expired
US5998581 Reductive alkylation of glycopeptide antibiotics 12 Nov, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Melinta Therap.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 28 Sep, 2020 US9682061
Payment of Maintenance Fee, 4th Year, Large Entity 28 Sep, 2020 US9649352
Payment of Maintenance Fee, 4th Year, Large Entity 28 Sep, 2020 US9649352
Payment of Maintenance Fee, 4th Year, Large Entity 28 Sep, 2020 US9682061
Payment of Maintenance Fee, 8th Year, Large Entity 15 Sep, 2020 US8420592
Payment of Maintenance Fee, 8th Year, Large Entity 15 Sep, 2020 US8420592
Recordation of Patent Grant Mailed 20 Jun, 2017 US9682061
Recordation of Patent Grant Mailed 20 Jun, 2017 US9682061
Patent Issue Date Used in PTA Calculation 20 Jun, 2017 US9682061
Patent Issue Date Used in PTA Calculation 20 Jun, 2017 US9682061
Email Notification 01 Jun, 2017 US9682061
Email Notification 01 Jun, 2017 US9682061
Issue Notification Mailed 31 May, 2017 US9682061
Issue Notification Mailed 31 May, 2017 US9682061
Recordation of Patent Grant Mailed 16 May, 2017 US9649352


Melinta Therap Drug Patents' Oppositions Filed in EPO

Melinta Therap drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 13, 2017, by Prüfer & Partner Mbb. This opposition was filed on patent number EP09810708A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP09810708A Jan, 2017 Prüfer & Partner mbB Granted and Under Opposition


Melinta Therap's Family Patents

Melinta Therap drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 29.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Melinta Therap Drug List

Given below is the complete list of Melinta Therap's drugs and the patents protecting them.


1. Kimyrsa

Kimyrsa is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9649352 High purity oritavancin and method of producing same 16 Jul, 2035
(10 years from now)
Active
US9682061 Methods of treating bacterial infections using oritavancin 26 Apr, 2030
(5 years from now)
Active
US8420592 Methods of treatment using single doses of oritavancin 29 Aug, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kimyrsa's drug page


2. Orbactiv

Orbactiv is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9649352 High purity oritavancin and method of producing same 16 Jul, 2035
(10 years from now)
Active
US9682061 Methods of treating bacterial infections using oritavancin 26 Apr, 2030
(5 years from now)
Active
US8420592 Methods of treatment using single doses of oritavancin 29 Aug, 2029
(4 years from now)
Active
US5840684 Glycopeptide antibiotic derivatives 24 Nov, 2020
(3 years ago)
Expired
US5998581 Reductive alkylation of glycopeptide antibiotics 12 Nov, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orbactiv's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List